Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 8/20 | 0.64 |
| ▸ | AKR1B10 | O60218 | 2/20 | 0.64 |
| ▸ | AKR1B1 | P15121 | 2/20 | 0.64 |
| ▸ | OR51E2 | Q9H255 | 1/20 | 0.64 |
| ▸ | GPBAR1 | Q8TDU6 | 4/20 | 0.58 |
| ▸ | HSD17B3 | P37058 | 4/20 | 0.58 |
| ▸ | LMNA | P02545 | 3/20 | 0.58 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.58 |
| ▸ | MEN1 | O00255 | 3/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.58 |
| ▸ | SHBG | P04278 | 2/20 | 0.58 |
| ▸ | SERPINA6 | P08185 | 2/20 | 0.58 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.58 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.58 |
| ▸ | G6PD | P11413 | 1/20 | 0.58 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.58 |
| ▸ | TSHR | P16473 | 1/20 | 0.58 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.58 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11518397 | 1.00 | CYP19A1 (0.64) | CYP19A1AKR1B10AKR1B1OR51E2GPBAR1 | |
| SCHEMBL6254375 | 1.00 | CYP19A1 (0.64) | CYP19A1AKR1B10AKR1B1OR51E2GPBAR1 | |
| SCHEMBL11042029 | 0.86 | CYP19A1 (0.66) | CYP19A1AKR1B10AKR1B1OR51E2GPBAR1 | |
| SCHEMBL3988004 | 0.86 | CYP19A1 (0.66) | CYP19A1AKR1B10AKR1B1OR51E2GPBAR1 | |
| SCHEMBL8533582 | 0.85 | CYP19A1 (0.64) | CYP19A1AKR1B10AKR1B1OR51E2GPBAR1 | |
| SCHEMBL11804277 | 0.82 | SHBG (0.47) | CYP19A1AKR1B10AKR1B1OR51E2GPBAR1 | |
| SCHEMBL8836157 | 0.81 | ABL1 (0.61) | CYP19A1AKR1B10AKR1B1OR51E2GPBAR1 | |
| SCHEMBL4886360 | 0.81 | CYP19A1 (0.44) | CYP19A1AKR1B10AKR1B1OR51E2GPBAR1 | |
| SCHEMBL497634 | 0.81 | G6PD (0.61) | CYP19A1AKR1B10AKR1B1OR51E2GPBAR1 | |
| SCHEMBL4927255 | 0.80 | CYP19A1 (0.56) | CYP19A1AKR1B10AKR1B1OR51E2GPBAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1499338-A4 | 7-HYDROXY-16ALPHA-FLUORO-5-ANDROSTEN-17-ONES AND 7-HYDROXY-16ALPHA-FLUORO-5-ANDROSTAN-17-ONES AND DERIVATIVES THEREOF | SCHWARTZ ARTHUR (US) | 2008-06-18 | — | — | EP | disclosed |
| EP-1499338-A1 | 7-HYDROXY-16ALPHA-FLUORO-5-ANDROSTEN-17-ONES AND 7-HYDROXY-16ALPHA-FLUORO-5-ANDROSTAN-17-ONES AND DERIVATIVES THEREOF | Schwartz, Arthur (US) | 2005-01-26 | — | — | EP | disclosed |
| US-20040034003-A1 | 7-Hydroxy-16alpha-fluoro-5-androsten-17-ones and 7-hydroxy-16alpha-fluoro-5-androstan-17-ones and derivatives thereof | BIOVIE INC. | 2004-02-19 | — | — | US | disclosed |
| WO-2003092722-A1 | 7-HYDROXY-16α-FLUORO-5-ANDROSTEN-17-ONES AND 7-HYDROXY-16α-FLUORO-5-ANDROSTAN-17-ONES AND DERIVATIVES THEREOF | SCHWARTZ ARTHUR (US) | 2003-11-13 | — | — | WO | disclosed |
| US-5804576-A | CANCER PREVENTIVE AGENTS, ANTI-OBESITY AGENTS, TREATMENT OF DIABETES | RESEARCH CORPORATION TECHNOLOGIES, INC. (US) | 1998-09-08 | — | — | US | disclosed |
| US-5714481-A | ADMINISTERING TO MAMMALIAN HOST A GLUCOSE-6-PHSOPHATE DEHYDROGENASE INHIBITOR, ANTICARCINOGENIC, ANTIOBASITY, ANTI-HYPERGLYCEMIC, ANTIAGING, ANTICHOLESTEROL AND ANTI-AUTOIMMUNE AGENT | RESEARCH CORPORATION TECHNOLOGIES, INC. (US) | 1998-02-03 | — | — | US | disclosed |
| US-5175154-A | Antiobesity, antidiabetic, antilipemic, anticholesterol agents | RESEARCH CORPORATION TECHNOLOGIES, INC. | 1992-12-29 | — | — | US | disclosed |
| US-5028631-A | Anticancer, antiobesity, anticholesterol | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 1991-07-02 | — | — | US | disclosed |
| US-5001119-A | 16-substituted androstanes and 16-substituted androstenes | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 1991-03-19 | — | — | US | disclosed |
| US-4898694-A | 17-Hydroxy-steroids | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 1990-02-06 | — | — | US | disclosed |
| US-4150126-A | ANTITUMOR AND ANTICARCINOGENIC AGENTS AND ANIBODY INHIBITORS | AKTIEBOLAGET LEO (SE) | 1979-04-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040034003-A1 | 7-Hydroxy-16alpha-fluoro-5-androsten-17-ones and 7-hydroxy-16alpha-fluoro-5-androstan-17-ones and derivatives thereof | HSD17B11, CYP17A1, NR5A1 | CYP19A1 6/4885AKR1B10 178/4885AKR1B1 144/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.